BridgeMD
Tests treatment safety and results for Dehiscence Wound
Official title Efficacy Evaluation of ActiGraft in Secondary Closure of Abdominal Surgical Wound Dehiscence
ClinicalTrials.gov ID: NCT04899466
What this study is testing
- What it's testing
- This is a prospective, single arm study, consisting of 20 women with abdominal surgical wound dehiscence that requires secondary closure. The participants will receive a weekly application of ActiGraft for 4 weeks, or until complete healing of the wound (the earlier of the two).
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, women only
You may be able to join if
- Age \>18 years
- Women that had a laparotomy no more than 3 weeks before accrual.
- Surgical wound dehiscence that requires a secondary closure.
- Time from wound dehiscence \>24 hours and \<6 days.
- The open wound includes epidermis, dermis and sub cutaneous fat.
You likely can't join if
- Patients with necrotizing fasciitis
- Patients with fascial dehiscence
- Cannot withdraw blood in the required amount (up to 18 mL per week).
- Known coagulation problems, abnormal thrombocytes level or if heparin is given intravenously. people who are taking oral anti-coagulants or...
- Pregnancy
- Subject is currently receiving (i.e., within the past 30 days) or scheduled to receive systemic steroids (Prednisone- more than 10mg/d or equivalent).
See the full eligibility criteria
- Age \>18 years
- Women that had a laparotomy no more than 3 weeks before accrual.
- Surgical wound dehiscence that requires a secondary closure.
- Time from wound dehiscence \>24 hours and \<6 days.
- The open wound includes epidermis, dermis and sub cutaneous fat.
- The patient can sign an informed consent form.
- Patients with necrotizing fasciitis
- Patients with fascial dehiscence
- Cannot withdraw blood in the required amount (up to 18 mL per week).
- Known coagulation problems, abnormal thrombocytes level or if heparin is given intravenously. people who are taking oral anti-coagulants or anti-agreganrts will not be excluded.
- Pregnancy
- Subject is currently receiving (i.e., within the past 30 days) or scheduled to receive systemic steroids (Prednisone- more than 10mg/d or equivalent).
The study team makes the final eligibility decision.
Where it's taking place
- Kfar Saba, Israel
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Kfar Saba, Israel. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.